4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines
- 5 June 2006
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 24 (23), 4975-4986
- https://doi.org/10.1016/j.vaccine.2006.03.042
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- The Requirement of Multimodal Therapy (Vaccine, Local Tumor Radiation, and Reduction of Suppressor Cells) to Eliminate Established TumorsClinical Cancer Research, 2005
- Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivoImmunology, 2004
- Tumor Expression of 4-1BB Ligand Sustains Tumor Lytic T CellsCancer Biology & Therapy, 2003
- 4-1BBL Enhances Anti-tumor Responses in the Presence or Absence of CD28 but CD28 Is Required for Protective Immunity against Parental TumorsCellular Immunology, 2001
- Immunomodulatory Gene Therapy With Interleukin 12 and 4-1BB Ligand: Long- Term Remission of Liver Metastases in a Mouse ModelJNCI Journal of the National Cancer Institute, 2000
- MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitopeEuropean Journal of Immunology, 1999
- Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathwayEuropean Journal of Immunology, 1998
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992
- Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus VaccineJNCI Journal of the National Cancer Institute, 1992
- RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes.The Journal of Experimental Medicine, 1992